Wall Street Analysts Weigh in on Top Healthcare Picks
Wall Street analysts are optimistic about several top healthcare picks, according to recent reports. Amgen (AMGN), Tectonic Therapeutic (TECX), and Revolution Medicines (RVMD) have all received bullish sentiments from leading analysts.
Matt Phipps of William Blair reiterated a Buy rating on Amgen in a report released today, with shares closing last Thursday at $438.00. This comes after BMO Capital also reiterated a Buy rating on the stock on August 17, with a price target of $450.00.
Tectonic Therapeutic has an analyst consensus of Strong Buy, with a price target consensus of $79.50, representing a potential upside from current levels. Mizuho Securities analyst Uy Ear reiterated a Buy rating on Tectonic Therapeutic today and set a price target of $85.00.
Revolution Medicines also received positive analysis, with Laura Prendergast from Stifel Nicolaus maintaining a Buy rating and setting a price target of $215.00. The company's shares closed last Thursday at $220.27, and the word on the Street suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $241.70 average price target.
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $394.73, representing a -8.9% downside. Analysts' success rates and returns vary, but overall the sector shows promise.